Trials / Unknown
UnknownNCT01891708
VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (estimated)
- Sponsor
- Li Liu · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
a. VEGFRs may be the biomarker which can predict the effect of bevacizumab in non small cell lung cancer
Detailed description
1. non small cell lung cancer (non squamous carcinoma) 2. ECOG 0-1 3. from 18-75 years old
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | bevacizumab, standard chemotherapy and radiation | the dose and application model of the three intervention are not specified by the sponsor who just observe the efficacy of the combination application of the three in non small cell lung cancer patients with brain metastasis once enrolled. |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2014-12-01
- Completion
- 2018-12-01
- First posted
- 2013-07-03
- Last updated
- 2013-07-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01891708. Inclusion in this directory is not an endorsement.